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Abstract
Objectives To assess the value ofMRI and diffusion-weighted
imaging (DWI) for diagnosing local tumour regrowth during
follow-up of organ preservation treatment after chemoradio-
therapy for rectal cancer.
Methods Seventy-two patients underwent organ preservation
treatment (chemoradiotherapy + transanal endoscopic micro-
surgery or Bwait-and-see^) and were followed with MRI in-
cluding DWI (1.5 T) every 3 -months during the first year and
6 months during following years. Two readers scored each
MRI for local regrowth using a confidence level, first on stan-
dard MRI, then on standard MRI+DWI. Histology and clini-
cal follow-up were the standard reference. Receiver operating
characteristic curves were constructed and areas under the
curve (AUC) and corresponding accuracy figures calculated
on a per-scan basis.
Results Four hundred and forty MRIs were assessed. Twelve
patients developed local regrowth. AUC/sensitivity/specifici-
ty for standardMRI were 0.95/58 %/98% (R1) and 0.96/58 %
/100 % (R2). For standard MRI+DWI, these numbers were
0.86/75 %/97 % (R1) and 0.98/75 %/100 % (R2). After
adding DWI, the number of equivocal scores decreased from
22 to 7 (R1) and from 40 to 20 (R2).
Conclusions Although there was no overall improvement in
diagnostic performance in terms of AUC, adding DWI im-
proved the sensitivity of MRI for diagnosing local tumour
regrowth and lowered the rate of equivocal MRIs.
Key Points
• DWI improves sensitivity for detecting local tumour re-
growth after organ preservation treatment.
• In particular, DWI can aid in detecting small local
recurrence.
• DWI reduces the number of equivocal scores.
Keywords Rectal neoplasms .Magnetic resonance imaging .
Diffusion . Recurrence . Organ preservation
Introduction
Nowadays, we are witnessing a paradigm shift in rectal cancer
treatment away from standard resection towards minimally
invasive surgery (transanal endoscopic microsurgery; TEM)
or non-operative management (Bwait-and-see^) in patients
showing a clinically near-complete or complete response to
neoadjuvant chemoradiotherapy (CRT)—albeit largely as part
of observational trials at this time. Rates of local regrowth
range from 6 to 25 % after TEM and from 5 to 13 % for
wait-and-see, and excellent survival rates of greater than
90 % have been reported for both strategies [1–6]. Thus far,
patients are generally followed using endoscopy and digital
examination. However, studies have suggested that imag-
ing—and MRI in particular—may also play an important role
in patient surveillance [1, 7], all the more because of the
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necessity to monitor the (extra-)mesorectal lymph nodes that
remain in situ and thus harbour the potential risk for tumour
regrowth. Given the novelty of organ preservation treatment,
no strong evidence yet exists regarding the potential role of
MRI. Moreover, the ideal follow-up schedule has not
yet been established. To date, reports from Brazil and
the United States have followed a scheme in which
imaging was performed Baccording to each patient’s
requirement^ [3, 6] or Bat the discretion of the treating
physicians^ [5]. In the study by the Maastricht group
imaging was routinely performed every 3–6 months
[1]. The primary aim of close surveillance is the detec-
tion of any potential tumour regrowth as early as pos-
sible so that salvage surgery can still be performed
without compromising the oncological outcome.
Morphological MRI is known to be less reliable for differ-
entiating between post-treatment effects (i.e. fibrosis or bowel
wall oedema after surgery/radiation) and tumours. From this
perspective, the addition of diffusion-weighted imaging
(DWI) may be beneficial. Various studies have shown the
benefit of DWI for the detection of malignancies [8].
In rectal cancer, many reports support its potential ben-
eficial role, especially in evaluating response to CRT
[9–14]. Furthermore, DWI can aid in differentiating re-
current disease within the pelvis from areas of post-ra-
diation/postoperative fibrosis [15, 16]. It may be partic-
ularly helpful for follow-up after organ preservation
treatment, since tumour regrowth in these patients is
typically still small and thus more difficult to detect
on standard MRI.
The aim of this study, therefore, was to evaluate the value
of MRI and test the hypothesis that adding DWI to standard
(T2-weighted) MRI is of value for the diagnosis of local tu-
mour regrowth during clinical follow-up of patients undergo-
ing organ preservation treatment.
Methods
Patients
This study retrospectively evaluated 72 consecutive rectal
cancer patients between September 2008 and July 2014 who
were managed with organ preservation treatment after chemo-
radiotherapy at Maastricht University Medical Centre. Forty-
nine patients were men, 23 were women, with a median age of
65 years (range 32–84). Seventeen patients with a small resid-
ual tumour (ycT1/2N0) after CRTwere treated with TEM, and
55 patients with a complete response (ycT0/N0) were follow-
ed according to a Bwait-and-see^ policy. The routine CRT
scheme consisted of 28×1.8 Gy+2×825 mg/m2/d cape-
citabine. The majority (66/72) of patients were treated/
followed as part of a clinical trial [1], and the remaining
six were followed Boff-study^ (e.g. because they were
included prior to the trial period or had comorbidity/
metastases excluding them from formal trial participa-
tion). MR imaging including DWI was routinely per-
formed every 3 months during the first year and every
6 months during the following years [1].
Table 1 Sequence parameters
T2-weighted FSE Diffusion-weighted MRI
DWIBS DWI-SPIR DWI-SPAIR
Repetition time 8456–9558 4808–4829 4971 4172–5241
Echo time 130–150 70 70 68–70
Number of slices 22–30 50 24 20–24
Slice thickness (mm) 3–5 5 5 5
FOV (mm) 200 440 320 320
Acquired in plane resolution (mm×mm) 0.78×1.14 2.50×3.11–3.18 1.82×2.31 1.82×2.27
Sensitivity encoding factor – 1.9–2 1.9 1.9
Echotrain length 25 1 1 1
Number of signal averages 2–6 4 5 5
Acquisition time (min:sec) 4:37–6:30 10:37–12:20 05:33 05:51–06:44
B-values – 0, (100), 500, 1000 0, 500, 1000 0, (25, 50, 100) 500,1000
Fatsuppression technique – STIR SPIR SPAIR
Echo planar imaging factor – 53–55 55 61
Abbreviations: STIR short TI inversion recovery, SPIR spectral presaturation with inversion recovery, SPAIR spectral attenuated inversion recovery.
During the study period, the DWIBS sequence was applied from September 2008 through December 2011, the DWI-SPIR sequence was used from
December 2011 through June 2012, and the DWI-SPAIR sequence was used from June 2012 through the end of the study period (July 2014)
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MR imaging
MR imaging was performed at 1.5 T (Intera [Achieva] or
Ingenia MRI systems; Philips Healthcare, Best, Netherlands)
using a phased-array surface coil with patients in feet-first
supine position. Patients did not receive bowel preparation.
The protocol included T2-weighted fast spin-echo sequences
in three planes and an axial diffusion-weighted sequence
(highest b-value b1000). Detailed scan parameters are provid-
ed in Table 1. Apparent diffusion coefficient (ADC) maps in
greyscale were automatically generated by the operating sys-
tem. The axial T2-weighted and DWI sequences were angled
in identical planes perpendicular to the rectal lumen at the site
of the former tumour bed or, in the case of a suspectedmass on
the planning images, perpendicular to the mass.
Image evaluation
Each individual follow-up MRI examination was assessed by
two readers (MJL andDMJL)with 9 (reader 1; R1) and 5 years
(reader 2; R2) of specific experience in reading rectal MRI.
The readers assessed the MRI examinations independently
and were blinded to each other’s results. They were aware of
the primary treatment (i.e. TEM or wait-and-see) and had
insight into the primary staging MRI and restaging MRI +
endoscopy (including biopsy results) performed 8 weeks after
completion of CRT, i.e. prior to initiation of the organ preser-
vation treatment/follow-up. The readers were blinded to his-
topathological outcome in the case of TEM surgery and to all
other data obtained during follow-up, including imaging, en-
doscopy, and biopsy results, information on any potential sal-
vage surgical procedures, and histopathological outcome.
For each individual MR examination, the readers first eval-
uated the standard T2-weighted images and recorded the like-
lihood of tumour regrowth using a five-point confidence level
scale (0=definitely no regrowth, 1=probably no regrowth, 2=
possibly no/possibly regrowth, 3=probably regrowth, and 4=
definitely regrowth). In the same reading session, the DWI
images (+ ADC map) were revealed, and the readers re-
evaluated the T2-weighted and DWI images together (side
by side) using the same confidence level score.
Standard of reference
All tumour regrowth was histologically confirmed by biopsy
and/or after surgical resection. In patients without regrowth,
the absence of a tumour was confirmed by a combination of
the following: (a) no abnormalities on corresponding endos-
copy, (b) negative biopsy results, and (c) no evidence of tu-
mour regrowth during clinical, endoscopic and imaging
follow-up over a median follow-up period of 38 months
(range 19–78 months).
Statistical analyses
Statistical analyses were performed using SPSS Statistics for
Windows (version 20.0; IBM Corp., Darmonk, NY, USA).
Diagnostic performance was assessed on a per-scan basis, in
which each individual MR examination was considered an
independent event. Receiver operating characteristic (ROC)
curve analyses were performed and areas under the ROC
curve (AUC) were calculated. Accuracy figures were calcu-
lated after dichotomisation of the scores with the cut-off (de-
fined before onset of the study) set between 2=possibly/pos-
sibly no regrowth and 3=probably regrowth. Kappa values
with quadratic kappa weighting were calculated to determine
interobserver agreement.
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Results
Patient and treatment characteristics
Baseline patient characteristics are given in Table 2. The 72
study patients together underwent a total of 440 follow-up
MRIs (range 1–13 per patient), of which 92 were performed
after TEM and 348 during wait-and-see. Twelve patients had
tumour regrowth (5/17 TEM patients and 7/55 wait-and-see
patients): regrowth of two tumours occurred within 6 months
(both during wait-and-see), seven between 6 and 12 months
(four after TEM, three during wait-and-see), and three after
12–24 months (one after TEM, two during wait-and-see). No
regrowth occurred after 24months of follow-up. The regrowth
was luminal (at the site of the previous tumour) in 10/12 pa-
tients; the other two involved nodal regrowth.
Effect of DWI on number of equivocal scores
On standard T2WMRI, R1 assigned an equivocal (confidence
level 2) score to 22/440 or 5% of the examinations (12% after
TEM, 3 % during wait-and-see) and R2 to 40/440 or 9 %
(16% after TEM, 7% during wait-and-see). After the addition
of DWI, the equivocal scores decreased to 7/440 or 2 % (1 %
after TEM, 2 % during wait-and-see) for R1 and 20/440 or
5 % (8 % after TEM, 4 % during wait-and-see) for R2. A
representative example of a case where the addition of DWI
increased the readers’ confidence is given in Fig. 1.
The distribution of equivocal scores during early
(≤6 months) and late (>6 months) follow-up and between
the wait-and-see and TEM groups is given in Table 3. The
majority of equivocal scores occurred during early follow-
up: 77 % (17/22; R1) and 53 % (21/40; R2) for standard
T2W MRI alone, and 71 % (5/7; R1) and 50 % (10/20; R2)
for T2W MRI + DWI. In the TEM group in particular, the
equivocal scores largely occurred within the first 6 months:
82 % (9/11; R1) and 67 % (10/15; R2) for T2W MRI, and
100 % (1/1; R1) and 57 % (4/7; R2) for T2WMRI + DWI. A
representative case in which equivocal scores changed over
long-term follow-up after TEM is given in Fig. 2.
Diagnostic performance
The ROC curves for both readers are displayed in Fig. 3.
AUCs were 0.95 (R1) and 0.96 (R2) for standard T2W
MRI, and 0.86 (R1) and 0.98 (R2) for standard T2W MRI +
DWI (p=0.16 for R1 and p=0.02 for R2). Diagnostic accura-
cy figures are given in Table 4. For R1, sensitivity and spec-
ificity were 58 % and 98 %, respectively, for standard T2W
MRI versus 75 % and 97 % for standard T2W MRI + DWI.
For R2, these numbers were 58 % and 100 % for standard
T2W MRI versus 75 % and 100 % for standard T2W MRI +
DWI. Themajority of false positives after the addition of DWI
Fig. 1 Example of a male patient who was followed according to a wait-
and-see policy and who developed local tumour regrowth at the location
of his primary rectal tumour after 21 months of follow-up. (a) Axial T2-
weighted image of the primary tumour (arrows) before chemoradiother-
apy. (b) Follow-up axial T2-weighted image of the former tumour
location at the time of the regrowth: no clear isointense mass or wall
thickening was observed. (c) Corresponding diffusion-weighted image
that clearly shows a focal area of high signal indicative of tumour re-
growth. This was later confirmed as a pT2 rectal tumour
Table 3 Distribution of
equivocal scores amongst patients
undergoing total endoscopic
microsurgery (TEM) and wait-
and-see and for those with early
and late follow-up
Number of equivocal scores (T2Wonly/T2W+DWI) TEM Wait-and-see TOTAL
R1 R2 R1 R2 R1 R2
Early (≤6 months) 9/1 10/4 8/4 11/6 17/5 21/10
Late (> 6 months) 2/0 5/3 3/2 14/7 5/2 19/10
TOTAL 11/1 15/7 11/6 25/13 22/7 40/20
Results are presented separately for T2-weighted MRI/T2-weighted MRI+DWI
R1 reader 1, R2 reader 2
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(10/12=83 % for R1 and 2/2=100 % for R2) occurred in
patients who had no histologically proven tumour regrowth
at the time of the Bfalse-positive^ finding, but developed tu-
mour regrowth later during follow-up.
Interobserver agreement
Overall, interobserver agreement between the two readers was
moderate for both standard T2-weightedMRI (κ 0.55) and the
combined reading of standard T2WMRI + DWI (κ 0.56). For
the Blate^ follow-up examinations (performed after 6 months
of follow-up), interobserver agreement was moderate for T2-
weighted MRI (κ 0.57) and good for T2W MRI + DWI (κ
0.64).
Discussion
AddingDWI to standard T2WMRI did not result in an overall
improvement in diagnostic performance in terms of AUC, but
it did result in improved sensitivity for the detection of local
tumour regrowth during surveillance of patients undergoing
organ preservation treatment after chemoradiotherapy: sensi-
tivity increased from 58 % to 75 % for two individual readers.
Fig. 2 Follow-up axial T2-weighted and diffusion-weighted images of a
male patient who underwent transanal endoscopic microsurgery (TEM)
after chemoradiotherapy. (a) Two months after the TEM procedure, the
axial T2-weighted images show a defect in the rectal wall, with fibrotic
changes at the TEM location (arrows). (b) On DWI, a focal high signal
intensity is visible, indicated by the circle. The readers interpreted this
high signal as suspicious for local tumour regrowth. (c) Five months later,
the T2-weighted images show a similar scar, with further increased fibro-
sis (arrows). (d) On the corresponding diffusion-weighted image, the
previous high signal has disappeared, and there is no remaining suspicion
of tumour regrowth. Long-term follow-up confirmed that this patient had
no tumour regrowth
Fig. 3 Receiver operating characteristic curves for the diagnostic
performance in the diagnosis of local tumour regrowth (on a per-scan
basis) for standard T2-weighted MRI only and T2-weighted MRI +
DWI. Areas under the curve are provided, with 95% confidence intervals
in parentheses
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A striking finding was that although the rate of Bfalse-
positive^ findings increased after the addition of DWI,
the majority of these false positives occurred in patients
who developed tumour regrowth later during follow-up.
Finally, the addition of DWI substantially reduced the
number of equivocal scores (from 22 to 7 for R1 and
from 40 to 20 for R2), thereby increasing the chance of
a conclusive MR outcome.
Our study is the largest to date focussing on the detection of
tumour regrowth with MRI during the surveillance of patients
treated with organ preservation. Previous studies (Colosio
et al. and Lambregts et al.) have focussed on imaging in pa-
tients after routine surgical treatment. In these studies, MRI
was performed only in the case of clinically suspected recur-
rence (clinical symptoms or rising carcinoembryonic antigen
levels). Colosio et al. [17] reported an increase in sensitivity of
7–16 % for two of three readers in a group of 52 surgically
treated rectal cancer patients. In their study, DWI was benefi-
cial only for the less experienced resident readers and not for a
senior reader. A similar study by Lambregts et al. found no
significant improvement in diagnostic accuracy with the addi-
tion of DWI in 42 patients after routine surgical resection [16].
We hypothesize that the disparity in results between our study
and these reports can be explained in part by the difference in
clinical setting. Symptomatic regrowth/recurrence is often di-
agnosed in a more advanced stage when morphological dis-
tortions in the tumour bed can be clearly visualised already
with standard MRI. However, in our cohort, where asymp-
tomatic patients were routinely monitored with repetitive
MR assessment, the regrowth was small (7–33 mm). These
cases of small regrowth are challenging to detect on standard
MRI, particularly within post-treatment fibrosis. In such cases,
the use of DWI can help the reader spot any suspicious signals
of tumour regrowth. In two of our study cases, DWI indeed
aided the detection of a small tumour regrowth that was not
detected on T2-weighted MRI (Fig. 1). In two other
cases, the addition of DWI increased the confidence of
R2 from level 3 (probably tumour regrowth) to level 4
(definitely tumour regrowth).
A striking finding in the present study was the relatively
high rate of false positives after the addition of DWI, particu-
larly for R1. Interestingly, the majority of these false positives
(10/12 for R1 and 2/2 for R2) occurred in patients who devel-
oped tumour regrowth later during follow-up. At the time of
the Bfalse-positive^ DWI findings, no changes suspicious for
tumour recurrence were visualised on endoscopy, and biopsy
results (when available) were negative. The latter served as the
standard of reference, and thus these patients were considered
false-positive on DWI at that time in our analyses. This raises
the question, however, of whether these false positives were
actual false positives on DWI or whether these DWI findings
might have been early features of regrowth. This would sug-
gest that in some cases, primarily those in which tumour
growth starts within the fibrotic mass without distortion of
the lumen, DWI signal changes may precede any visible
changes on endoscopy. The remaining two false-positive
cases for R1 both occurred within the first 6 months of fol-
low-up (one after TEM, one during wait-and-see).
Shortly after treatment, postoperative/post-radiation in-
flammatory changes may still be present, in which case
an accumulation of inflammatory cells, granulomas, and
lymphoid aggregates can lead to relatively high cellular-
ity and thus restricted diffusion. In patients with inflam-
matory bowel disease, this phenomenon is used as a
diagnostic criterion on DWI to detect active inflamma-
tion [18, 19], but in the setting of surveillance of pa-
tients after organ preservation treatment, these effects
may hamper image interpretation and mimic a tumour.
One of the benefits of DWI is that it offered a con-
clusive outcome in several cases (5–9 % of all MRIs)
where the T2W MRI resulted in equivocal scores. In
clinical practice, an equivocal MRI would require addi-
tional exams. Adding a DWI sequence may thus render
such additional exams unnecessary. The effect of DWI
Table 4 Diagnostic performance (on a per-scan basis) for T2-weighted MRI only versus T2-weighted MRI + DWI combined for diagnosing local
tumor regrowth after chemoradiotherapy followed by organ-saving treatment
T2W T2W + DWI
R1 R2 R1 R2
Sensitivity (%) 58 (29–84) [7/12] 58 (29–84) [7/12] 75 (43–93) [9/12] 75 (43–93) [9/12]
Specificity (%) 98 (96–99) [418/428] 100 (99–100) [428/428] 97 (99–100) [414/428] 100 (98–100) [426/428]
PPV (%) 41 (19–67) [7/17] 100 (56–100) [7/7] 39 (20–61) [9/23] 82 (48–79) [9/11]
NPV (%) 99 (97–100) [418/423] 98 (97–99) [428/433] 99 (98–100) [414/417] 99 (98–100) [426/429]
Accuracy (%) 97 (94–98) [425/440] 99 (97–100) [435/440] 96 (94–98) [423/440] 99 (97–100) [435/440]
No. of equivocal scores (confidence level 2) 5 [22/440] 9 [40/440] 2 [7/440] 5 [20/440]
Note: Numbers in parentheses are 95 % confidence intervals; numbers in brackets are raw data
R1 reader 1, R2 reader 2, PPV positive predictive value, NPV negative predictive value
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was most apparent in patients followed after TEM: the
rate of equivocal scores on standard T2W MRI was 12–
16 % after TEM versus only 3–7 % for the wait-and-see
group. Furthermore, within the TEM group, most of the
equivocal scores (67–82 %) occurred during the first
6 months of follow-up. This makes sense, since post-
surgical effects such as oedema and tissue inflammation
will still be present early after surgery, rendering the
images more difficult to interpret. In patients undergoing
wait-and-see, such postsurgical effects are absent,
allowing for easier interpretation of T2-weighted im-
ages, and thus explaining the higher confidence for both
readers. In the wait-and-see group, the beneficial effect
of DWI in increasing the readers’ confidence was there-
fore less obvious.
Our study is limited by its retrospective nature. The
results are based on a per-scan assessment of individual
MR examinations. This setting was chosen to reflect
daily practice and to gain insight into the strengths
and weaknesses of MRI and DWI during regulated fol-
low-up, but may not translate into the true overall diag-
nostic performance of MRI and DWI on a patient level.
However, the 17 % increase in sensitivity can be direct-
ly translated to the effect on sensitivity at a patient
level, given that only one event/regrowth occurred per
patient. Given the limited number of cases of local re-
growth, the confidence intervals (particularly for sensi-
tivity and positive predictive value) are relatively wide.
Interobserver agreement was moderate for T2-weighted
MRI and moderate to good after the addition of DWI.
The moderate agreement is likely attributable in part to
the fact that one of the two readers assigned a relatively
large number of equivocal scores, particularly for T2W
MRI. Finally, in the setting of protocols used for daily
clinical practice, a variation in sequence parameters was
present as a result of protocol optimization over the
years. Although the reading was designed in a way that
only visual evaluation of DWI was performed using the
same b-value images (b1000), variations in image qual-
ity may have introduced some bias.
In conclusion, this study shows that although the ad-
dition of DWI to a standard rectal MRI protocol may
not result in a significant overall improvement in diag-
nostic performance in terms of area under the ROC
curve, it can help to improve the sensitivity of MRI in
detecting small local recurrence during the surveillance
of patients after organ preservation treatment. In fact, it
may be true that in the case of tumour regrowth, chang-
es in DWI precede any changes detectable at endoscopy.
A second important benefit from the addition of DWI is
that it reduces the number of equivocal findings, partic-
ularly during early follow-up after TEM surgery, and
thus enhances the chance of a conclusive MR outcome.
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